Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) CEO Sells $1,040,500.00 in Stock

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) CEO Richard Scott Struthers sold 50,000 shares of the business’s stock in a transaction dated Friday, June 16th. The stock was sold at an average price of $20.81, for a total transaction of $1,040,500.00. Following the sale, the chief executive officer now owns 680,805 shares in the company, […]

Related Keywords

Israel ,Zurcher Kantonalbank Zurich Cantonalbank ,Robertw Baird ,Richard Scott Struthers ,Piper Sandler ,Quarter For Crinetics Pharmaceuticals ,Tower Research Capital ,Cubist Systematic Strategies ,News Ratings For Crinetics Pharmaceuticals Daily ,Hedge Funds Weigh In On Crinetics Pharmaceuticals ,Securities Exchange Commission ,Nasdaq ,Crinetics Pharmaceuticals ,Bourgeon Capital Management ,Psagot Value Holdings Ltd ,Crinetics Pharmaceuticals Inc ,Crinetics Pharmaceuticals Company Profile ,Crinetics Pharmaceuticals Stock Down ,Get Rating ,Scott Struthers ,Exchange Commission ,Pharmaceuticals Stock Down ,Research Capital ,Value Holdings ,Capital Management ,Kantonalbank Zurich Cantonalbank ,Systematic Strategies ,Crinetics Pharmaceuticals Daily ,Nasdaq Crnx ,Crnx ,Medical ,Insider Trading ,Nsider Trades ,Stocks ,